Search

19 Feb 2024: 22498 12,600 people will help test screening for a common heart condition which is known to be a trigger for strokes. ... up across the NHS.”/p pJon Sussex, the Chief Economist at RAND Europe and health economics lead for BRACE, says: “The timing for

23 Feb 2024: randomised controlled trial (RCT) that will test the effectiveness and cost effectiveness of treatment with a Polypill (fixed dose of 3 antihypertensive agents and one cholesterol-lowering agent) compared with conventional ... a polypill approach and a

23 Feb 2024: 3. To assess what previous published economic analyses there may be that evaluation the cost-effectiveness of different prescription lengths.The results of the review will feed into economic analyses comparing

23 Feb 2024: £878,580. Further Information, References and Publications. Run by the MRC Epidemiology Unit, HSR economists are leading the economic evaluation alongside the study.

23 Feb 2024: Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial. ... Feasibility of the cardiac output response to stress test in suspected heart failure patients.

23 Feb 2024: equipment, or delays receiving patient information or test results. However, little is.

22 Sep 2023: Understanding market fundamentalism is important because of its tendency to promote not only financial but also social instability, not least through gross economic inequality.

23 Feb 2024: The Adherence App Study is a randomised feasibility trial which will test a novel smartphone Application (App) called Healthera, designed to increase adherence to medication in patients prescribed blood pressure lowering ... Health service costs and

19 Feb 2024: Diagnostic tests such as the faecal immunochemical test (FIT) were being used more often to rule out colorectal cancer – sometimes before a face-to-face appointment could be arranged./p blockquotepInterviews ... These screening programmes work, but at

23 Feb 2024: Principal research question:. There are large expectations that by applying insights from behavioural economics to alter “choice architecture”, health-related and other behaviours can be changed in low cost ways that